The section includes sign-on letters, petitions, and collective statements.
Materials in this section
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Four years after MPP and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers, generic G/P is not available anywhere. More
World Hepatitis Summit 2022 Statement
The participants of the third World Hepatitis Summit called on governments, global health agencies and donors to fund comprehensive hepatitis programs. More
Advocates Demand Continuous Catalytic Investment Towards Viral Hepatitis Elimination
An open letter sent to Unitaid demands continuous investment towards HBV and HCV elimination, and to address the needs of 354 million people living with viral hepatitis worldwide. More
#FreeChangsha3: Wrongfully Detained HIV/Viral Hepatitis Activists
Three Chinese lawyers and advocates, who work on employment discrimination and disability justice for people living with HIV and viral hepatitis, have been wrongfully detained in China. More
Civil Society Groups Tell UNITAID: Support Access Mechanisms Led by Civil Society, Not the Pharmaceutical Industry
Letters from global groups express deep concerns about the Medicines Patent Pool’s entry into hepatitis C treatment
A coalition of civil society groups, including people with HCV, HIV, and HCV/HIV coinfection, expressed deep concerns over UNITAID’s upcoming decision to expand the MPP’s mandate for HCV treatment. More
Gilead Sciences: Provide Sofosbuvir Now!
The TRT-5 and the CHV are requesting individual and organizational sign-ons to a letter urging Gilead to provide early access to sofosbuvir for people with the most urgent need. More